ING Groep NV Boosts Position in Bristol Myers Squibb Company $BMY

ING Groep NV raised its stake in Bristol Myers Squibb Company (NYSE:BMY) by 227.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 963,133 shares of the biopharmaceutical company’s stock after buying an additional 669,447 shares during the period. ING Groep NV’s holdings in Bristol Myers Squibb were worth $43,437,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also added to or reduced their stakes in the company. Darwin Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb in the second quarter valued at approximately $25,000. Harbor Capital Advisors Inc. raised its position in Bristol Myers Squibb by 107.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 313 shares in the last quarter. Total Investment Management Inc. purchased a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth $38,000. Twin Peaks Wealth Advisors LLC bought a new position in shares of Bristol Myers Squibb during the 2nd quarter worth $40,000. Finally, Mark Sheptoff Financial Planning LLC grew its position in shares of Bristol Myers Squibb by 233.3% during the 2nd quarter. Mark Sheptoff Financial Planning LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 700 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Stock Up 0.1%

NYSE:BMY opened at $60.82 on Wednesday. The company’s 50-day simple moving average is $54.82 and its 200-day simple moving average is $49.20. The company has a debt-to-equity ratio of 2.39, a quick ratio of 1.17 and a current ratio of 1.27. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $63.33. The stock has a market capitalization of $123.81 billion, a P/E ratio of 17.63, a P/E/G ratio of 0.17 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 70.30%. The firm had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. During the same period in the previous year, the company earned $1.67 EPS. The company’s revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Friday, January 2nd were paid a dividend of $0.63 per share. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date was Friday, January 2nd. This represents a $2.52 annualized dividend and a yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 73.04%.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Weiss Ratings restated a “hold (c-)” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. Leerink Partners boosted their price target on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a report on Tuesday, January 13th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, November 24th. Guggenheim reiterated a “buy” rating and set a $72.00 price objective (up from $62.00) on shares of Bristol Myers Squibb in a research note on Friday. Finally, Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Eight research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $59.20.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.